AR048878A1 - Composiciones topicas de metadona y metodos para usarlas - Google Patents

Composiciones topicas de metadona y metodos para usarlas

Info

Publication number
AR048878A1
AR048878A1 ARP050101672A ARP050101672A AR048878A1 AR 048878 A1 AR048878 A1 AR 048878A1 AR P050101672 A ARP050101672 A AR P050101672A AR P050101672 A ARP050101672 A AR P050101672A AR 048878 A1 AR048878 A1 AR 048878A1
Authority
AR
Argentina
Prior art keywords
metadona
methods
compositions
topic compositions
topic
Prior art date
Application number
ARP050101672A
Other languages
English (en)
Spanish (es)
Original Assignee
Caldwell Galer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35393974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR048878(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Caldwell Galer Inc filed Critical Caldwell Galer Inc
Publication of AR048878A1 publication Critical patent/AR048878A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ARP050101672A 2004-04-29 2005-04-28 Composiciones topicas de metadona y metodos para usarlas AR048878A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56668604P 2004-04-29 2004-04-29

Publications (1)

Publication Number Publication Date
AR048878A1 true AR048878A1 (es) 2006-06-07

Family

ID=35393974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101672A AR048878A1 (es) 2004-04-29 2005-04-28 Composiciones topicas de metadona y metodos para usarlas

Country Status (21)

Country Link
US (1) US20050244486A1 (https=)
EP (1) EP1740162A4 (https=)
JP (1) JP5250257B2 (https=)
KR (1) KR20070007850A (https=)
CN (1) CN1976689A (https=)
AR (1) AR048878A1 (https=)
AU (2) AU2005244214B2 (https=)
BR (1) BRPI0510428A (https=)
CA (1) CA2563489C (https=)
CR (1) CR8722A (https=)
EA (1) EA011423B1 (https=)
IL (1) IL178661A0 (https=)
ME (1) MEP25008A (https=)
MX (1) MXPA06012563A (https=)
NO (1) NO20065455L (https=)
NZ (1) NZ550963A (https=)
RS (1) RS20060605A (https=)
TW (1) TW200605870A (https=)
UA (1) UA88464C2 (https=)
WO (1) WO2005110381A1 (https=)
ZA (1) ZA200608923B (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1774964B1 (en) * 2005-10-13 2014-08-06 Nitto Denko Corporation Nicotine transdermal preparation and production method thereof
WO2008051527A2 (en) * 2006-10-23 2008-05-02 Psivida, Inc. Sustained release of agents for localized pain management
JP5704801B2 (ja) * 2008-08-21 2015-04-22 ニプロパッチ株式会社 粘着性組成物及び経皮吸収型製剤
GB2481619B (en) * 2010-06-30 2012-06-20 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013168021A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168012A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
WO2013168000A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
WO2013168004A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of fibromyalgia pain
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
JP2015518854A (ja) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド 多発性硬化症の治療のための組成物および方法
NZ701832A (en) 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en) 2012-09-08 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
SG11201509782TA (en) 2013-06-04 2015-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
NZ736131A (en) 2014-09-26 2019-04-26 Cellix Bio Private Ltd Compositions and methods for the treatment of epilepsy and neurological disorders
ES2799309T3 (es) 2014-09-29 2020-12-16 Cellix Bio Private Ltd Compuestos y composiciones para el tratamiento de esclerosis múltiple
JP6564868B2 (ja) 2014-10-27 2019-08-21 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 多発性硬化症の治療のための、フマル酸モノメチルエステルとピペラジン又はエチレンジアミンとの３つの成分の塩
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
WO2016088132A1 (en) 2014-12-01 2016-06-09 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
SG11201705524SA (en) 2015-01-06 2017-08-30 Cellix Bio Private Ltd Compositions and methods for the treatment of inflammation and pain
WO2022155179A2 (en) * 2021-01-14 2022-07-21 The Trustees Of Indiana University Methods to predict effects of perioperative administration of methadone to optimize pain relief and avoid adverse effects

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5316759A (en) * 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
EP0399432B1 (en) * 1989-05-25 1994-06-22 Takeda Chemical Industries, Ltd. Transdermal therapeutic composition
US5580876A (en) * 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
AU5551394A (en) * 1992-11-09 1994-06-08 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5883115A (en) * 1992-11-09 1999-03-16 Pharmetrix Division Technical Chemicals & Products, Inc. Transdermal delivery of the eutomer of a chiral drug
US5589480A (en) * 1994-08-17 1996-12-31 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE19642043A1 (de) * 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US6787149B1 (en) * 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
EP1021204B1 (en) * 1997-09-26 2005-12-28 Noven Pharmaceuticals, Inc. Bioadhesive compositions and methods for topical administration of active agents
US6143278A (en) * 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
GB9804885D0 (en) * 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
AP1224A (en) * 1998-03-19 2003-11-14 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
DE19850517B4 (de) * 1998-11-03 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines wirkstoffhaltigen transdermalen therapeutischen Systems in einer Kombinationsbehandlung mit und ohne Ultraschall
GB9828480D0 (en) * 1998-12-24 1999-02-17 Dermatech Limited Transdermal drug delivery system
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
AU3104301A (en) * 2000-01-20 2001-07-31 Noven Pharmaceuticals, Inc. Compositions and methods to effect the release profile in the transdermal administration of active agents
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2003523405A (ja) * 2000-02-22 2003-08-05 セレジー カナダ インコーポレイテッド 睡眠改善のための方法および組成物
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
DE60220703T2 (de) * 2001-10-22 2008-02-07 3M Innovative Properties Co., St. Paul Verpackung für transdermale/transmucosale pflaster
US6713470B2 (en) * 2002-01-22 2004-03-30 Ml Laboratories Plc Method of treatment

Also Published As

Publication number Publication date
EP1740162A4 (en) 2009-11-18
BRPI0510428A (pt) 2007-10-30
TW200605870A (en) 2006-02-16
UA88464C2 (ru) 2009-10-26
RS20060605A (sr) 2008-09-29
US20050244486A1 (en) 2005-11-03
AU2005244214B2 (en) 2010-02-18
CA2563489C (en) 2013-06-18
JP2007538008A (ja) 2007-12-27
IL178661A0 (en) 2007-02-11
CA2563489A1 (en) 2005-11-24
NZ550963A (en) 2008-11-28
AU2010201707A1 (en) 2010-05-20
CN1976689A (zh) 2007-06-06
KR20070007850A (ko) 2007-01-16
EA011423B1 (ru) 2009-02-27
AU2005244214A1 (en) 2005-11-24
NO20065455L (no) 2007-01-19
EA200601776A1 (ru) 2007-04-27
EP1740162A1 (en) 2007-01-10
ZA200608923B (en) 2008-05-28
MXPA06012563A (es) 2007-03-21
CR8722A (es) 2007-05-30
MEP25008A (en) 2010-10-10
WO2005110381A1 (en) 2005-11-24
JP5250257B2 (ja) 2013-07-31

Similar Documents

Publication Publication Date Title
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
ECSP109852A (es) Uso de homo y copolímeros para la estabilización de formulaciones de principios activos
UY27720A1 (es) Aroilpiridinonas monocíclicas,
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
AR109263A2 (es) Composición que comprende moxidectina
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
CL2008000442A1 (es) Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
CL2011000729A1 (es) Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
GT200600520A (es) Agentes antibacterianos
CL2009000665A1 (es) Compuestos derivados de pirrolidinilo; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la ansiedad, depresion o ambas.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
BRPI0617294B8 (pt) composição farmacêutica em gel hidroalcóolico e uso de testosterona
CL2004001012A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
UY28622A1 (es) Agentes antibacterianos de quinolona
AR058141A1 (es) Composiciones topicas de n,2,3 -trimetil-2- isopropilbutamida para el alivio del dolor y metodos para usarlas
DE602004014787D1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
AR052048A1 (es) Composiciones farmaceuticas para el tratamiento de la celulitis
CL2004001010A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
CL2004001007A1 (es) Compuestos derivados de macrolitos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
BRPI0518478A2 (pt) composiÇço de verniz para uso cosmÉtico ou farmacÊutico e utilizaÇço de solvente de origem vegetal

Legal Events

Date Code Title Description
FB Suspension of granting procedure